Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ibrahim

Showing results (631-640 of 664) with videos related to

Pageof 67
Sort By:
Cancer Cell|December 11, 2007
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxelAhmed Ashour Ahmed, Anthony D Mills, Ashraf E K Ibrahim, et al.
Breast (Edinburgh, Scotland)|April 26, 2021
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropeniaMark Clemons, Dean Fergusson, Anil A Joy, et al.
Clinical and Vaccine Immunology : CVI|July 31, 2009
Establishment of reference values of CD4 and CD8 lymphocyte subsets in healthy Nigerian adultsD K Oladepo, E O Idigbe, R A Audu, et al.
Breast Cancer Research and Treatment|June 12, 2016
Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancerBanu K Arun, Yun Gong, Diane Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeksMarjorie C Green, Aman U Buzdar, Terry Smith, et al.
Vaccines|January 22, 2022
Determinants of Obtaining COVID-19 Vaccination among Health Care Workers with Access to Free COVID-19 Vaccination: A Cross-Sectional StudyMariam R Elkhayat, Maiada K Hashem, Ahmed T Helal, et al.
Cancer|June 5, 2003
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinomaW Fraser Symmans, Mark Ayers, Edwin A Clark, et al.
JAMA Oncology|November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and BevacizumabReva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trialAman U Buzdar, S Eva Singletary, Vicente Valero, et al.
British Journal of Cancer|May 18, 2019
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatmentBora Lim, Rashmi K Murthy, Jangsoon Lee, et al.
Pageof 67

Showing results (631-640 of 664) with videos related to

Sort By:
Pageof 67
Cancer Cell|December 11, 2007
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxelAhmed Ashour Ahmed, Anthony D Mills, Ashraf E K Ibrahim, et al.
Breast (Edinburgh, Scotland)|April 26, 2021
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropeniaMark Clemons, Dean Fergusson, Anil A Joy, et al.
Clinical and Vaccine Immunology : CVI|July 31, 2009
Establishment of reference values of CD4 and CD8 lymphocyte subsets in healthy Nigerian adultsD K Oladepo, E O Idigbe, R A Audu, et al.
Breast Cancer Research and Treatment|June 12, 2016
Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancerBanu K Arun, Yun Gong, Diane Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeksMarjorie C Green, Aman U Buzdar, Terry Smith, et al.
Vaccines|January 22, 2022
Determinants of Obtaining COVID-19 Vaccination among Health Care Workers with Access to Free COVID-19 Vaccination: A Cross-Sectional StudyMariam R Elkhayat, Maiada K Hashem, Ahmed T Helal, et al.
Cancer|June 5, 2003
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinomaW Fraser Symmans, Mark Ayers, Edwin A Clark, et al.
JAMA Oncology|November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and BevacizumabReva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trialAman U Buzdar, S Eva Singletary, Vicente Valero, et al.
British Journal of Cancer|May 18, 2019
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatmentBora Lim, Rashmi K Murthy, Jangsoon Lee, et al.
Pageof 67